By Colin Kellaher


AC Immune SA on Tuesday said a Phase 2 study evaluating the safety and efficacy of its investigational anti-tau monoclonal antibody semorinemab in mild-to-moderate Alzheimer's disease met one of its co-primary endpoints.

The Lausanne, Switzerland, clinical-stage biopharmaceutical company said semorinemab showed a statistically significant reduction in cognitive decline from baseline by 43.6% compared with placebo in the study. The study was being conducted by Roche Holding AG's Genentech unit, AC Immune's collaboration partner in Alzheimer's disease since 2006.

AC Immune said there was no effect on the other co-primary endpoint of reducing the rate of functional decline from baseline, adding that semorinemab was well tolerated in the study, with an acceptable safety profile and no unanticipated safety signals.

AC Immune said the study marks the first time that a monoclonal anti-tau antibody therapy has had a therapeutic impact on cognition in the mild-to-moderate Alzheimer's patient population.

AC Immune said Genentech plans to continue the open-label portion of the study and to submit top-line results for presentation at a conference in November.

Shares of AC Immune, which closed Monday at $6.99, surged nearly 70% in premarket trading Tuesday.


Write to Colin Kellaher at


(END) Dow Jones Newswires

August 31, 2021 08:18 ET (12:18 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more AC Immune Charts.
Historical Stock Chart
From May 2021 to May 2022 Click Here for more AC Immune Charts.